- Home
- PLUR vs TVRD Comparison
PLUR vs TVRD Comparison
Compare PLUR & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLUR | TVRD |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.9M | 34.1M |
| IPO Year | 2001 | N/A |
Fundamental Metrics
Financial Performance| Metric | PLUR | TVRD |
|---|---|---|
| Price | $3.31 | $3.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $12.00 | ★ $51.67 |
| AVG Volume (30 Days) | 6.3K | ★ 37.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,336,000.00 | N/A |
| Revenue This Year | $97.38 | N/A |
| Revenue Next Year | $293.97 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 309.82 | N/A |
| 52 Week Low | $2.82 | $3.50 |
| 52 Week High | $7.13 | $43.65 |
Technical Indicators
Market Signals| Indicator | PLUR | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 51.27 | 47.01 |
| Support Level | $3.13 | $3.81 |
| Resistance Level | $3.91 | $4.45 |
| Average True Range (ATR) | 0.16 | 0.21 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 44.07 | 38.12 |
Price Performance
Historical ComparisonAbout PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.